BiotechTube
Freedom Biosciences

Freedom Biosciences

Boston, United States· Est.
freedombio.co
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $5M

Overview

Freedom Biosciences is a private, preclinical-stage biotech founded in 2021, headquartered in Boston, USA. The company is built upon the pioneering ketamine research of its co-founder, Dr. John Krystal, and aims to develop next-generation, ketamine-based and combination neuropsychiatric drugs. Its pipeline includes programs targeting treatment-resistant depression and comorbid conditions, with a core strategy of improving upon the first-generation therapies like esketamine. The company is led by CEO Dina Burkitbayeva and combines deep scientific expertise with venture investment experience in the psychedelics sector.

PsychiatryMental HealthSubstance Use Disorders

Technology Platform

A discovery platform for identifying synergistic combination therapies, leveraging known pharmacology of ketamine, 5ht2a agonists, and other neuropsychiatric compounds to enhance efficacy, safety, and duration of effect.

Funding History

1
Total raised:$5M
Seed$5M

Opportunities

The massive unmet need in treatment-resistant depression and comorbid substance use disorders presents a multi-billion dollar market.
The company's platform, built on foundational ketamine research, is positioned to create improved therapies that address key limitations of first-generation drugs like esketamine, such as short duration of effect and abuse potential.
Success could establish a new standard of care in neuropsychiatry.

Risk Factors

High clinical risk associated with proving the superiority of novel combination therapies.
Evolving and complex regulatory pathways for controlled substance-based treatments.
Intense competition from both large pharma and well-funded biotech startups in the psychedelics space.
Dependence on raising sufficient capital in a challenging funding environment to advance its pipeline.

Competitive Landscape

Freedom Bio competes in the rapidly growing field of novel neuropsychiatric therapeutics, facing competition from large pharma (e.g., Johnson & Johnson with Spravato) and a host of biotech peers like Compass Pathways (psilocybin for TRD), Atai Life Sciences (portfolio approach), and others developing next-generation psychedelic and ketamine-based therapies. Differentiation hinges on demonstrating superior clinical profiles through its combination platform.

More companies in Neuroscience & CNS →More companies in United States →